Skip to main content
SpringerLink
Log in

External beam radiation therapy: role of androgen deprivation

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1. A, B
Fig. 2.

References

  1. Bolla M, Gonzalez D, Warde P, et al. (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295–300

    Google Scholar 

  2. Bolla M, Collette L, Blank L, et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103–106

    Article  CAS  PubMed  Google Scholar 

  3. Buchsbaum J, Elshaikh M, Kupelian P, et al. (2001) Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment is an independent predictor of outcome. Int J Radiat Oncol Biol Phys 51:169

    Article  Google Scholar 

  4. American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035–1041

    Article  PubMed  Google Scholar 

  5. D'Amico AV, Schultz D, Loffredo M, et al. (2000) Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 284:1280–1283

    Article  PubMed  Google Scholar 

  6. Davies-Johns T, Reddy C, Kupelian P (2000) Localized prostate cancer treated with radiotherapy: who benefits from hormonal therapy? Int J Radiat Oncol Biol Phys 48:170

    Article  Google Scholar 

  7. Fowler JE, Jr, Bigler SA, Kolski JM, et al. (1998) Early results of a prospective study of hormone therapy for patients with locally advanced prostate carcinoma. Cancer 82:1112–1117

    Article  PubMed  Google Scholar 

  8. Gleave ME, Goldenberg SL, Chin JL, et al. (2001) Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 166:500–506, discussion 506–507

    PubMed  Google Scholar 

  9. Hanks GE, Lu JD, Machtay M, et al. (2000) RTOG protocol 92–02: a phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 48:112

    Article  Google Scholar 

  10. Hanks GE, Hanlon AL, Pinover WH, et al. (2000) Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 46:823–832

    Article  CAS  PubMed  Google Scholar 

  11. Hanks GE, Hanlon AL, Pinover WH, et al. (1999) Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am 5:152–158

    CAS  PubMed  Google Scholar 

  12. Jhaveri FM, Klein EA, Kupelian PA, et al. (1999) Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 17:3167–3172

    CAS  PubMed  Google Scholar 

  13. Joon DL, Hasegawa M, Sikes C, et al. (1997) Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 38:1071–1077

    PubMed  Google Scholar 

  14. Klotz LH, Goldenberg SL, Jewett M, et al. (1999) CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. Urology 53:757–763

    Article  PubMed  Google Scholar 

  15. Kupelian PA, Mohan DS, Lyons J, et al. (2000) Higher than standard radiation doses (72 Gy or greater) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 46:567–574

    Article  PubMed  Google Scholar 

  16. Kupelian PA, Buchsbaum JC, Reddy CA, et al. (2001) Radiation dose response in patients with favorable localized prostate cancer (stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10). Int J Radiat Oncol Biol Phys 50:621–625

    Article  PubMed  Google Scholar 

  17. Kupelian PA, Buchsbaum JC, Elshaikh M, et al. (2002) Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Cancer 95:2302–2307

    Article  PubMed  Google Scholar 

  18. Kupelian PA, Willoughby TR (2001) Short-course, intensity-modulated radiotherapy for localized prostate cancer. Cancer J 7:421–426

    CAS  PubMed  Google Scholar 

  19. Kupelian PA (1999) Improvement in overall survival for patients with localized prostate cancer with higher than standard radiation doses: preliminary results. J Urol 161:386

    Google Scholar 

  20. Laverdiere J, Gomez JL, Cusan L, et al. (1997) Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37:247–252

    CAS  PubMed  Google Scholar 

  21. Lawton CA, Winter K, Byhardt R, et al. (1997) Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85–31). Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 38:931–939

    Article  PubMed  Google Scholar 

  22. Lawton CA, Winter K, Murray K, et al. (2001) Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85–31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49:937–946

    Article  PubMed  Google Scholar 

  23. Lyons JA, Kupelian PA, Mohan DS, et al. (2000) Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology 55:85–90

    Article  CAS  PubMed  Google Scholar 

  24. Martinez AA, Yan D, Lockman D, et al. (2001) Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer. Int J Radiat Oncol Biol Phys 50:1226–1234

    Article  PubMed  Google Scholar 

  25. Pilepich MV, Caplan R, Byhardt RW, et al. (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85–31. J Clin Oncol 15:1013–1021

    CAS  PubMed  Google Scholar 

  26. Pilepich M, Krall J, Al-Sarraf M, et al. (1995) Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the RTOG. Urology 45:616–623

    Article  CAS  PubMed  Google Scholar 

  27. Pilepich MV, Winter K, John MJ, et al. (2001) Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243–1252

    Article  PubMed  Google Scholar 

  28. Pollack A, Zagars GK, Starkschall G, et al. (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105

    Article  PubMed  Google Scholar 

  29. Roach M, 3rd, DeSilvio M, Lawton C, et al. (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21:1904–1911

    Article  PubMed  Google Scholar 

  30. See WA, Wirth MP, McLeod DG, et al. (2002) Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 168:429–435

    PubMed  Google Scholar 

  31. Shipley WU, Lu JD, Pilepich MV, et al. (2002) Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86–10. Int J Radiat Oncol Biol Phys 54:1302–1310

    Article  PubMed  Google Scholar 

  32. Soloway MS, Pareek K, Sharifi R, et al. (2002) Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167:112–116

    PubMed  Google Scholar 

  33. Soloway MS, Sharifi R, Wajsman Z, et al. (1995) Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154:424–428

    PubMed  Google Scholar 

  34. Zagars GK, Pollack A, von Eschenbach AC (1997) Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer 80:764–775

    Article  PubMed  Google Scholar 

  35. Zagars GK, Pollack A, Smith LG (1999) Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 44:809–819

    Article  PubMed  Google Scholar 

  36. Zagars GK, Johnson DE, von Eschenbach AC, et al. (1988) Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 14:1085–1091

    PubMed  Google Scholar 

  37. Zelefsky MJ, Leibel SA, Gaudin PB, et al. (1998) Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41:491–500

    Article  CAS  PubMed  Google Scholar 

  38. Zelefsky MJ, Fuks Z, Hunt M, et al. (2002) High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111–1116

    Article  PubMed  Google Scholar 

  39. Zietman AL, Dallow KC, McManus PA, et al. (1996) Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. Urology 47:236–239

    Article  PubMed  Google Scholar 

  40. Zietman AL, Prince EA, Nakfoor BM, et al. (1997) Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 38:1067–1070

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, M.D. Anderson Cancer Center Orlando, 1400 South Orange Avenue, Orlando, FL 32806, USA

    Patrick Kupelian

Authors
  1. Patrick Kupelian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Kupelian.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kupelian, P. External beam radiation therapy: role of androgen deprivation. World J Urol 21, 190–199 (2003). https://doi.org/10.1007/s00345-003-0355-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-003-0355-y

Keywords

Search

Navigation